Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple pump flow measure predict organ health in heart device patients?

NCT ID NCT07633535

Knowledge-focused Sponsor: Gaziantep City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with end-stage heart failure who have a mechanical heart pump (LVAD). It checks whether the pump's flow rate, adjusted for body size, is linked to liver and kidney function and the chance of being readmitted to the hospital. The goal is to see if this measure could help doctors monitor patients better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, doctors might use the LVAD index to better predict organ function and readmission risk in heart failure patients with these devices.
What could go wrong
This is a small, observational study with only 34 participants, so results may not apply broadly. It looks for associations, not cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

34 people

The number who actually took part.

Started

Oct 2022

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with end-stage heart failure who underwent first-time continuous-flow left ventricular assist device implantation and were followed for at least six months. The study population included patients supported with either HVAD or HeartMate 3 devices during routine clinical follow-up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis of end-stage heart failure * First-time continuous-flow left ventricular assist device implantation * Implanted with either an HVAD or HeartMate 3 left ventricular assist device * Minimum follow-up period of six months Exclusion Criteria: * Incomplete data * Declined participation * HeartMate II pump implantation * Significant aortic valve dysfunction, including moderate or severe aortic regurgitation or stenosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

advanced heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage heart failure Left ventricular assist device Mechanical circulatory support

Contacts and locations

Locations

  • Akdeniz University Faculty of Medicine

    Antalya, 07070, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.